A 52-year-old male from rural Maharashtra presents to the primary health centre with a 3-month history of progressive dyspnea and orthopnea. On examination, he has a blood pressure of 160/100 mmHg, heart rate 92/min, and bilateral ankle edema. Chest X-ray shows cardiomegaly and pulmonary congestion. ECG reveals left ventricular hypertrophy. The patient reports no prior screening or treatment for hypertension. According to NPCDCS guidelines, which of the following is the most appropriate next step in management at the PHC level?

Explanation

## Clinical Context This patient presents with uncontrolled hypertension (Stage 2) complicated by signs of heart failure (orthopnea, edema, cardiomegaly, pulmonary congestion) and end-organ damage (LVH). This is a hypertensive emergency with acute decompensation requiring prompt intervention. ## NPCDCS Management Algorithm for Hypertension **Key Point:** NPCDCS (National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Disease and Stroke) emphasizes a tiered approach to NCD management. At the PHC level, the focus is on **early detection, risk stratification, and initiation of evidence-based pharmacotherapy** for symptomatic or high-risk patients, with referral for specialist evaluation when complications are present. **High-Yield:** Patients with hypertension-related complications (heart failure, LVH, renal involvement) require **immediate antihypertensive therapy at the PHC level** combined with **urgent referral to a secondary/tertiary centre** for investigation and specialist management. Delaying pharmacotherapy in a symptomatic patient is contraindicated. ## Why This Answer Is Correct Option 0 (Initiate amlodipine 5 mg daily and refer to district hospital) aligns with NPCDCS guidelines because: 1. **Immediate pharmacotherapy:** A calcium channel blocker (amlodipine) is a safe, first-line agent suitable for PHC initiation in a hypertensive patient with signs of organ damage. 2. **Urgent referral:** The presence of clinical heart failure, LVH, and cardiomegaly mandates specialist evaluation (echocardiography, ejection fraction assessment) to guide further therapy (ACE inhibitor/ARB addition, diuretic dosing). 3. **PHC-to-secondary linkage:** This reflects the NPCDCS model of task-shifting: PHC initiates treatment; secondary centre confirms diagnosis and optimizes therapy. ## NPCDCS Hypertension Management Pathway ```mermaid flowchart TD A[Hypertension detected at PHC]:::outcome --> B{Symptomatic or<br/>complications?}:::decision B -->|No complications| C[Lifestyle counselling<br/>+ Antihypertensive if BP ≥140/90]:::action B -->|Complications present<br/>LVH, HF, renal disease| D[Start antihypertensive<br/>at PHC immediately]:::action D --> E[Refer to district hospital<br/>for investigations & specialist review]:::action C --> F[Follow-up at PHC<br/>3 months]:::action E --> G[Echocardiography,<br/>renal function, EF assessment]:::action G --> H[Optimize therapy<br/>at secondary centre]:::action ``` ## Why Each Distractor Is Wrong | Option | Reason | |--------|--------| | Option 1: "Home BP monitoring for 2 weeks before starting therapy" | **Dangerous delay.** A symptomatic patient with clinical heart failure, LVH, and BP 160/100 requires **immediate pharmacotherapy**, not a 2-week observation period. This risks acute decompensation and cardiorenal syndrome. | | Option 2: "Diuretics and ACE inhibitors only after confirming LVEF at tertiary centre" | **Misinterprets NPCDCS scope.** While specialist confirmation of EF is needed for optimal drug selection, **first-line antihypertensive therapy should NOT be delayed** pending tertiary investigation. PHC can and should initiate a calcium channel blocker or beta-blocker immediately. | | Option 3: "Lifestyle modifications alone; follow-up in 3 months" | **Contraindicated.** A patient with symptomatic heart failure and uncontrolled hypertension requires **pharmacotherapy now**, not lifestyle advice alone. A 3-month delay risks acute pulmonary edema, arrhythmia, and stroke. | ## Clinical Pearl **NPCDCS emphasizes that PHC-level providers are empowered to initiate first-line antihypertensive agents in all patients with BP ≥140/90 mmHg or those with symptomatic hypertension.** Referral to secondary/tertiary care is for confirmation of complications, specialist optimization, and management of refractory disease—not as a prerequisite to starting treatment. ## High-Yield Takeaway **Do not delay antihypertensive therapy at PHC while awaiting specialist investigations.** Initiate + refer simultaneously.